Advert - Swedish Orphan Biovitrum (Sobi)

For failing to include accurate information about the side effects of Alprolix (eftrenonacog alfa) and not reflecting the available information, Sobi was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 7.2 - Making a misleading claim

Clause 7.4 - Making an unsubstantiated claim

Clause 7.9 - Making claims that did not reflect the available evidence regarding possible adverse reactions

Clause 9.1 - Failing to maintain high standards.